EYPT EyePoint Corp: Long-Term Debt to Capital Coefficient

Symbol and logo of brand EyePoint Corp (EYPT)

EyePoint Pharmaceuticals (EYPT) owns a state-of-the-art American facility for producing long-term ocular implants with impeccable cleanliness control. This price action chart below captures the 0.13 metric. The company is recognized as an expert in retinal treatment due to its unique drug delivery methods. Stable management, bridging the gap between science and business, is currently focused on the final testing stages of its core technological developments.

EYPT - EyePoint Pharmaceuticals Inc Long-Term Debt to Equity over the range 07/04/2022 - 10/28/2026

Comprehensive metric breakdowns and analytics for EyePoint Pharmaceuticals (EYPT)

- price and consensus price forecast:
Quote Chart EyePoint Pharmaceuticals Inc|EYPT - Analyst Consensus Forecast
- market capitalization data:
Market Value EyePoint Pharmaceuticals, Inc.|EYPT - Enterprise Value
- book capitalization data:
Book Value per Share EyePoint Pharmaceuticals|EYPT - Company Book Value|Market Value to Book Value eyepointpharma.com|EYPT - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio EyePoint Pharmaceuticals|EYPT - Long-Term Debt to Capital|Short-Term Debt to Capital eyepointpharma.com|EYPT - Company Total Debt|Debt to Net Assets Ratio EyePoint Pharmaceuticals, Inc.|EYPT - Company Long-Term Debts|Short-Term Debt EyePoint Pharmaceuticals
Initial company analysis:EYPT, EyePoint Pharmaceuticals Inc
Core merchandise of EyePoint Pharmaceuticals

The efficiency of the operating model is determined by the long-term debt-to-equity ratio, which allows for an assessment of the business's reliance on external financing during scaling. This long-term debt leverage reflects the stability of EyePoint Pharmaceuticals (EYPT) during the market launch of the Durasert microimplant and the completion of EYP-1901 clinical trials, demonstrating a balance between borrowed capital and investment autonomy.

Who EyePoint Pharmaceuticals competes with

Long-Term Liabilities to Equity Alcon Inc|Bausch + Lomb Corp (BLCO) - Long-Term Debt to Capital|Long-Term Debt to Capital Coefficient Glaukos Medical (GKOS)|Long-Term Debt to Capital APLS (Apellis Pharmaceuticals)|Belite Bio Pharma - Long-Term Debt to Capital|Long-Term Debt to Equity Ocular Therapeutix, Inc. (OCUL)|HROW: Long-Term Debt to Capital Coefficient|VRDN (Viridian Pharma) - Long-Term Debt to Equity|LENZ Corp (LENZ) - Long-Term Debt to Equity Ratio|OCS (Oculis Holding) - Long-Term Debt to Capital|Long-Term Debt to Capital kodiak.com (KOD)|Aldeyra Therapeutics (ALDX) - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient kalarx.com (KALA)|IRD: Long-Term Debt to Capital|OKYO - Long-Term Liabilities to Capital|ADVM (Adverum) - Long-Term Debt to Equity Ratio|OTLK - Long-Term Liabilities to Capital|Long-Term Debt to Capital CLSD|NBY (NovaBay Pharmaceuticals, Inc.) - Long-Term Liabilities to Capital|KPRX: Long-Term Debt to Equity|Ratio of Long-Term Indebtedness to Capital Alimera|Eyenovia, Inc. - Long-Term Debt to Capital|Long-Term Liabilities to Capital guardionhealth.com GHSI|OCUP: Long-Term Debt to Equity Ratio|Long-Term Liabilities to Capital Opthea Ltd OPT